What is the role of inflammation in the pathogenesis of prostate cancer?

BJU International

Volumn 99, Issue 5, 2007, Pages 966-968

  Goldstraw, Miles A ^a   Fitzpatrick, John M ^c   Kirby, Roger S ^a,b  

^a London Clinic Cancer Centre   (United Kingdom)

^b Prostate Centre   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; GLUTATHIONE TRANSFERASE P1; MACROPHAGE SCAVENGER RECEPTOR 1; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR; RIBONUCLEASE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONDYLOMA; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GONORRHEA; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NOTE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATION; MALE; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 34247139662     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06731.x     Document Type: Note

References (16)

1. Armitage J, Emberton M. Is it time to reconsider the role of inflammation in the pathogenesis of lower urinary tract symptoms? BJU Int 2005; 96: 745-6
2. Nelson WG, De Marzo AM, De Weese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-12
3. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/ or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-81
4. Hayes RB, Pottern LM, Strickler H et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000; 82: 718-25
5. Taylor ML, Mainous AG 3rd, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 37: 506-12
6. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83
7. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002; 13: 427-34
8. Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-80
9. Leitzmann MF, Stampfer MJ, Ma J et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1108-11
10. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90: 93-9
11. Madaan S, Abel PD, Chaudhary KS et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86: 736-41
12. Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61: 8617-23
13. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 2006;164: 984-9
14. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673-84
15. Nelson WG, De Marzo AM, Deweese TL et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001; 952: 135-44
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-81